Adjuvant early and late cardioprotective therapy: Access to the heart

Cardiovascular Research

Volumn 94, Issue 2, 2012, Pages 226-236

  Hinkel, Rabea ^a   Boekstegers, Peter ^a   Kupatt, Christian ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Munich Heart Alliance   (Germany)

Author keywords

Acute myocardial infarction; Application route; Reperfusion injury

Indexed keywords

ADENOSINE; ATRIAL NATRIURETIC FACTOR; CARDIOVASCULAR AGENT; CARIPORIDE; COMPLEMENTARY DNA; CYCLOSPORIN A; EPOETIN ALPHA; GLUTATHIONE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; NICORANDIL; NITROPRUSSIDE SODIUM; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACUTE HEART INFARCTION; ADJUVANT THERAPY; BONE MARROW CELL; CATHETER; CD34 SELECTION; ENDOTHELIAL PROGENITOR CELL; EPICARDIUM; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; ISCHEMIC POSTCONDITIONING; MYOBLAST; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW;

CARDIOTONIC AGENTS; CHEMOTHERAPY, ADJUVANT; HUMANS; ISCHEMIC POSTCONDITIONING; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY;

EID: 84860183583     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs075     Document Type: Review

References (110)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010;121:e46-e215.
2. Suero JA, Marso SP, Jones PG, Laster SB, Huber KC, Giorgi LV et al. Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. J Am Coll Cardiol 2001;38:409-414. (Pubitemid 32721768)
3. White HD, Chew DP. Acute myocardial infarction. Lancet 2008;372:570-584.
4. Yellon DM, Baxter GF. Reperfusion injury revisited: is there a role for growth factor signaling in limiting lethal reperfusion injury? Trends Cardiovasc Med 1999;9:245-249.
5. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357: 1121-1135.
6. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 1999;79:609-634. (Pubitemid 29210931)
7. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002;105:656-662. (Pubitemid 34123444)
8. Ito H. No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med 2006;3:499-506. (Pubitemid 44288463)
9. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004;61:481-497. (Pubitemid 38210154)
10. Kung G, Konstantinidis K, Kitsis RN. Programmed necrosis, not apoptosis, in the heart. Circ Res 2011;108:1017-1036.
11. Boekstegers P, von Degenfeld G, Giehrl W, Heinrich D, Hullin R, Kupatt C et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. Gene Ther 2000;7:232-240. (Pubitemid 30113772)
12. Kupatt C, Hinkel R, Horstkotte J, Deiss M, von Bruhl ML, Bilzer M et al. Selective retroinfusion of GSH and cariporide attenuates myocardial ischemia-reperfusion injury in a preclinical pig model. Cardiovasc Res 2004;61:530-537. (Pubitemid 38210158)
13. Kupatt C, Hinkel R, Lamparter M, von Brühl ML, Pohl T, Horstkotte J et al. Retroinfusion of embryonic endothelial progenitor cells attenuates ischemia-reperfusion injury in pigs: role of phosphatidylinositol 3-kinase/AKT kinase. Circulation 2005; 112:I117-I122. (Pubitemid 41266662)
14. Kupatt C, Horstkotte J, Vlastos GA, Pfosser A, Lebherz C, Semisch M et al. Embryonic endothelial progenitor cells expressing a broad range of proangiogenic and remodeling factors enhance vascularization and tissue recovery in acute and chronic ischemia. FASEB J 2005;19:1576-1578. (Pubitemid 41279036)
15. Arslan F, Smeets MB, O'Neill LA, Keogh B, McGuirk P, Timmers L et al. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation 2010;121:80-90.
16. Oshima Y, Ouchi N, Shimano M, Pimentel DR, Papanicolaou KN, Panse KD et al. Activin A and follistatin-like 3 determine the susceptibility of heart to ischemic injury. Circulation 2009;120:1606-1615.
17. Nakamura T, Mizuno S, Matsumoto K, Sawa Y, Matsuda H, Nakamura T. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 2000;106:1511-1519. (Pubitemid 32038589)
18. Yang L, Jiang JG, Drouin LM, Agbandje-McKenna M, Chen CL, Qiao CP et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci USA 2009;106:3946-3951.
19. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008;16:1073-1080. (Pubitemid 351737072)
20. Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 2011;305:1863-1872.
21. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007;370: 1483-1493. (Pubitemid 47625560)
22. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999;34: 1711-1720.
23. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005;45:1775-1780. (Pubitemid 40779856)
24. Giordano FJ, Ping P, McKirnan MD, Nozaki S, DeMaria AN, Dillmann WH et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996;2:534-539. (Pubitemid 26151517)
25. Katz MG, Swain JD, White JD, Low D, Stedman H, Bridges CR. Cardiac gene therapy: optimization of gene delivery techniques in vivo. Hum Gene Ther 2010;21: 371-380.
26. Mariani JA, Kaye DM. Delivery of gene and cellular therapies for heart disease. J Cardiovasc Transl Res 2010;3:417-426.
27. Emani SM, Shah AS, Bowman MK, Emani S, Wilson K, Glower DD et al. Catheterbased intracoronary myocardial adenoviral gene delivery: importance of intraluminal seal and infusion flow rate. Mol Ther 2003;8:306-313. (Pubitemid 37062840)
28. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000;101:2154-2159. (Pubitemid 30253043)
29. Desmet W, Bogaert J, Dubois C, Sinnaeve P, Adriaenssens T, Pappas C et al. Highdose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J 2011;32:867-877.
30. Amit G, Cafri C, Yaroslavtsev S, Fuchs S, Paltiel O, Abu-Ful A et al. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J 2006;152:887.e9-814.e14.
31. Boekstegers P, Kupatt C. Current concepts and applications of coronary venous retroinfusion. Basic Res Cardiol 2004;99:373-381. (Pubitemid 39462359)
32. Müller OJ, Katus HA, Bekeredjian R. Targeting the heart with gene therapy-optimized gene delivery methods. Cardiovasc Res 2007;73:453-462. (Pubitemid 46084926)
33. Kaye DM, Preovolos A, Marshall T, Byrne M, Hoshijima M, Hajjar R et al. Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J Am Coll Cardiol 2007;50: 253-260. (Pubitemid 47031573)
34. Hou D, Youssef EA, Brinton TJ, Zhang P, Rogers P, Price ET et al. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation 2005;112: I150-I156. (Pubitemid 41266667)
35. Fukushima S, Coppen SR, Varela-Carver A, Brindley G, Yamahara K, Sarathchandra P et al. Enhanced efficiency of superoxide dismutase-induced cardioprotection by retrograde intracoronary administration. Cardiovasc Res 2006;69:459-465. (Pubitemid 43098802)
36. Fukushima S, Coppen SR, Varela-Carver A, Yamahara K, Sarathchandra P, Smolenski RT et al. A novel strategy for myocardial protection by combined antibody therapy inhibiting both P-selectin and intercellular adhesion molecule-1 via retrograde intracoronary route. Circulation 2006;114:I251-I256. (Pubitemid 44297159)
37. Boekstegers P, Peter W, von Degenfield G, Nienaber CA, Abend M, Rehders TC et al. Preservation of regional myocardial function and myocardial oxygen tension during acute ischemia in pigs: comparison of selective synchronized suction and retroinfusion of coronary veins to synchronized coronary venous retroperfusion. J Am Coll Cardiol 1994;23:459-469. (Pubitemid 24049379)
38. Boekstegers P, Giehrl W, von Degenfield G, Steinbeck G. Selective suction and pressure-regulated retroinfusion: an effective and safe approach to retrograde protection against myocardial ischemia in patients undergoing normal and high risk percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1998;31:1525-1533. (Pubitemid 28273294)
39. Pohl T, Giehrl W, Reichart B, Kupatt C, Raake P, Paul S et al. Retroinfusionsupported stenting in high-risk patients for percutaneous intervention and bypass surgery: results of the prospective randomized myoprotect I study. Catheter Cardiovasc Interv 2004;62:323-330. (Pubitemid 38868868)
40. Hinkel R, El-Aouni C, Olson T, Horstkotte J, Mayer S, Müller S et al. Thymosin b4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection. Circulation 2008;117:2232-2240.
41. Kupatt C, Dessy C, Hinkel R, Raake P, Daneau G, Bouzin C et al. Heat shock protein 90 transfection reduces ischemia-reperfusion-induced myocardial dysfunction via reciprocal endothelial NO synthase serine 1177 phosphorylation and threonine 495 dephosphorylation. Arterioscler Thromb Vasc Biol 2004;24:1435-1441. (Pubitemid 39050437)
42. Kupatt C, Wichels R, Deiß M, Molnar A, Lebherz C, Raake P et al. Retroinfusion of NFkB decoy oligonucleotide extends cardioprotection achieved by CD18 inhibition in a preclinical study of myocardial ischemia and retroinfusion in pigs. Gene Ther 2002;9:518-526. (Pubitemid 34449772)
43. Kupatt C, Hinkel R, Pfosser A, El-Aouni C, Wuchrer A, Fritz A et al. Cotransfection of vascular endothelial growth factor-A and platelet-derived growth factor-B via recombinant adeno-associated virus resolves chronic ischemic malperfusion: role of vessel maturation. J Am Coll Cardiol 2010;56:414-422.
44. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-1136. (Pubitemid 17174962)
45. Hausenloy DJ, Tsang A, Yellon DM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 2005;15:69-75. (Pubitemid 40693390)
46. Murphy E. Primary and secondary signaling pathways in early preconditioning that converge on the mitochondria to produce cardioprotection. Circ Res 2004;94:7-16. (Pubitemid 38064093)
47. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285:H579-H588. (Pubitemid 36885888)
48. Skyschally A, van Caster P, Iliodromitis EK, Schulz R, Kremastinos DT, Heusch G. Ischemic postconditioning: experimental models and protocol algorithms. Basic Res Cardiol 2009;104:469-483.
49. Manintveld OC, Te Lintel HM, van den Bos EJ, Suurenbroek GM, Dekkers DH, Verdouw PD et al. Cardiac effects of postconditioning depend critically on the duration of index ischemia. Am J Physiol Heart Circ Physiol 2007;292:H1551- H1560. (Pubitemid 46377144)
50. Vinten-Johansen J, Granfeldt A, Mykytenko J, Undyala VV, Dong Y, Przyklenk K. The multidimensional physiological responses to postconditioning. Antioxid Redox Signal 2011;14:791-810.
51. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I et al. Postconditioning the human heart. Circulation 2005;112:2143-2148. (Pubitemid 41475808)
52. Yang XC, Liu Y, Wang LF, Cui L, Wang T, Ge YG et al. Reduction in myocardial infarct size by postconditioning in patients after percutaneous coronary intervention. J Invasive Cardiol 2007;19:424-430. (Pubitemid 47509466)
53. Zhao WS, Xu L, Wang LF, Zhang L, Zhang ZY, Liu Y et al. A 60-s postconditioning protocol by percutaneous coronary intervention inhibits myocardial apoptosis in patients with acute myocardial infarction. Apoptosis 2009;14:1204-1211.
54. Freixa X, Bellera N, Ortiz-Perez JT, Jimenez M, Pare C, Bosch X et al. Ischaemic postconditioning revisited: lack of effects on infarct size following primary percutaneous coronary intervention. Eur Heart J 2012;33:103-112.
55. Schmidt MR, Smerup M, Konstantinov IE, Shimizu M, Li J, Cheung M et al. Intermittent peripheral tissue ischemia during coronary ischemia reduces myocardial infarction through a KATP-dependent mechanism: first demonstration of remote ischemic perconditioning. Am J Physiol Heart Circ Physiol 2007;292:H1883-H1890. (Pubitemid 46572412)
56. Xin P, Zhu W, Li J, Ma S, Wang L, Liu M et al. Combined local ischemic postconditioning and remote perconditioning recapitulate cardioprotective effects of local ischemic preconditioning. Am J Physiol Heart Circ Physiol 2010;298:H1819-H1831.
57. Bøtker HE, Kharbanda R, Schmidt MR, Bøttcher M, Kaltoft AK, Terkelsen CJ et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 2010;375:727-734.
58. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359: 473-481.
59. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004;292:344-350. (Pubitemid 38944258)
60. Raake PW, Hinkel R, Müller S, Delker S, Kreuzpointner R, Kupatt C et al. Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors. Gene Ther 2008;15:12-17. (Pubitemid 350284205)
61. Lai NC, Roth DM, Gao MH, Fine S, Head BP, Zhu J et al. Intracoronary delivery of adenovirus encoding adenylyl cyclase VT increases left ventricular function and cAMP-generating capacity. Circulation 2000;102:2396-2401.
62. Dib N, Menasche P, Bartunek JJ, Zeiher AM, Terzic A, Chronos NA et al. Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: a report of the International Society for Cardiovascular Translational Research. JACC Cardiovasc Interv 2010;3:265-275.
63. Dib N, Khawaja H, Varner S, McCarthy M, Campbell A. Cell therapy for cardiovascular disease: a comparison of methods of delivery. J Cardiovasc Transl Res 2011;4: 177-181.
64. Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 2007;167:989-997. (Pubitemid 46835786)
65. Lipinski MJ, Biondi-Zoccai GG, Abbate A, Khianey R, Sheiban I, Bartunek J et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol 2007;50:1761-1767. (Pubitemid 47600592)
66. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002;106:3009-3017. (Pubitemid 35440281)
67. Assmus B, Honold J, Schachinger V, Britten MB, Fischer-Rasokat U, Lehmann R et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006;355:1222-1232. (Pubitemid 44427446)
68. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006;355:1210-1221. (Pubitemid 44427445)
69. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004;364:141-148. (Pubitemid 38891685)
70. Strauer BE, Brehm M, Zeus T, Bartsch T, Schannwell C, Antke C et al. Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT Study. J Am Coll Cardiol 2005;46:1651-1658. (Pubitemid 41531618)
71. Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the Late-TIME randomized trial. JAMA 2011;306:2110-2119.
72. Hayase M, del Monte F, Kawase Y, MacNeill BD, McGregor J, Yoneyama R et al. Catheter-based antegrade intracoronary viral gene delivery with coronary venous blockade. Am J Physiol Heart Circ Physiol 2005;288:H2995-H3000. (Pubitemid 40720685)
73. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2011;124:304-313.
74. Raake P, von Degenfield G, Hinkel R, Vachenauer R, Sandner T, Beller S et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins: comparison with surgical and percutaneous intramyocardial gene delivery. J Am Coll Cardiol 2004;44:1124-1129. (Pubitemid 39165150)
75. Kupatt C, Hinkel R, von Bruhl ML, Pohl T, Horstkotte J, Raake P et al. Endothelial nitric oxide synthase overexpression provides a functionally relevant angiogenic switch in hibernating pig myocardium. J Am Coll Cardiol 2007;49:1575-1584. (Pubitemid 46517952)
76. Rezaee M, Yeung AC, Altman P, Lubbe D, Takeshi S, Schwartz RS et al. Evaluation of the percutaneous intramyocardial injection for local myocardial treatment. Catheter Cardiovasc Interv 2001;53:271-276. (Pubitemid 32532196)
77. de la Fuente LM, Stertzer SH, Argentieri J, Penaloza E, Miano J, Koziner B et al. Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter: 1-year follow-up in an open-label, nonrandomized, singlecenter pilot study (the TABMMI study). Am Heart J 2007;154:79-87.
78. Psaltis PJ, Zannettino AC, Gronthos S, Worthley SG. Intramyocardial navigation and mapping for stem cell delivery. J Cardiovasc Transl Res 2010;3:135-146.
79. Stewart DJ, Kutryk MJB, Fitchett D, Freeman M, Camack N, Su YH et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther 2009;17:1109-1115.
80. Kastrup J, Jørgensen E, Rück A, Tägil K, Glogar D, Ruzyllo W et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris: a randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 2005;45:982-988. (Pubitemid 40432426)
81. Kastrup J, Jørgensen E, Fuchs S, Nikol S, Bøtker HE, Gyöngyösi M et al. A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial. EuroIntervention 2011;6:813-818.
82. Charwat S, Lang I, Dettke M, Graf S, Nyolczas N, Hemetsberger R et al. Effect of intramyocardial delivery of autologous bone marrow mononuclear stem cells on the regional myocardial perfusion. NOGA-guided subanalysis of the MYSTAR prospective randomised study. Thromb Haemost 2010;103:564-571.
83. LosordoDW, Henry TD, Davidson C, Sup Lee J, Costa MA, Bass T et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res 2011;109:428-436.
84. McTiernan CF, Mathier MA, Zhu X, Xiao X, Klein E, Swan CH et al. Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts. Gene Ther 2007;14:1613-1622. (Pubitemid 350143187)
85. Higuchi K, Ayach B, Sato T, Chen MY, Devine SP, Rasaiah VI et al. Direct injection of kit ligand-2 lentivirus improves cardiac repair and rescues mice post-myocardial infarction. Mol Ther 2009;17:262-268.
86. Rengo G, Lymperopoulos A, Zincarelli C, Donniacuo M, Soltys S, Rabinowitz JE et al. Myocardial adeno-associated virus serotype 6-bARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 2009;119:89-98.
87. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701-715.
88. Stewart DJ, Hilton JD, Arnold JMO, Gregoire J, Rivard A, Archer SL et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF121 (AdVEGF121) versus maximum medical treatment. Gene Ther 2006;13:1503-1511. (Pubitemid 44574158)
89. Kilian EG, Sadoni S, Vicol C, Kelly R, van Hulst K, Schwaiger M et al. Myocardial transfection of hypoxia inducible factor-1a via an adenoviral vector during coronary artery bypass grafting-a multicenter phase I and safety study. Circulation Journal 2010;74:916-924.
90. Larose E, Proulx G, Voisine P, Rodés-Cabau J, De Larochelliere R, Rossignol G et al. Percutaneous versus surgical delivery of autologous myoblasts after chronic myocardial infarction: an in vivo cardiovascular magnetic resonance study. Catheter Cardiovasc Interv 2010;75:120-127.
91. Menasche P, Alfieri O, Janssens S, McKenna W, Reichenspurner H, Trinquart L et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 2008; 117:1189-1200. (Pubitemid 351552018)
92. Mocini D, Staibano M, Mele L, Giannantoni P, Menichella G, Colivicchi F et al. Autologous bone marrow mononuclear cell transplantation in patients undergoing coronary artery bypass grafting. Am Heart J 2006;151:192-197. (Pubitemid 41815354)
93. Laham RJ, Post M, Rezaee M, Donnell-Fink L, Wykrzykowska JJ, Lee SU et al. Transendocardial and transepicardial intramyocardial fibroblast growth factor-2 administration: myocardial and tissue distribution. Drug Metab Dispos 2005;33:1101-1107. (Pubitemid 41043751)
94. French BA, MazurW, Geske RS, Bolli R. Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. Circulation 1994;90:2414-2424.
95. Baldazzi F, Jørgensen E, Ripa RS, Kastrup J. Release of biomarkers of myocardial damage after direct intramyocardial injection of genes and stem cells via the percutaneous transluminal route. Eur Heart J 2008;29:1819-1826.
96. Leong-Poi H, Le E, Rim SJ, Sakuma T, Kaul S, Wei K. Quantification of myocardial perfusion and determination of coronary stenosis severity during hyperemia using real-time myocardial contrast echocardiography. J Am Soc Echocardiogr 2001;14: 1173-1182. (Pubitemid 33144383)
97. Unger EC, Hersh E, Vannan M, Matsunaga TO, McCreery T. Local drug and gene delivery through microbubbles. Prog Cardiovasc Dis 2001;44:45-54. (Pubitemid 32807854)
98. Unger EC, Hersh E, Vannan M, McCreery T. Gene delivery using ultrasound contrast agents. Echocardiography 2001;18:355-361. (Pubitemid 32579099)
99. Unger EC, Matsunaga TO, McCreery T, Schumann P, Sweitzer R, Quigley R. Therapeutic applications of microbubbles. Eur J Radiol 2002;42:160-168. (Pubitemid 34303309)
100. Miller MW. Gene transfection and drug delivery. Ultrasound Med Biol 2000;26(Suppl. 1):S59-S62. (Pubitemid 30229950)
101. Mayer CR, Bekeredjian R. Ultrasonic gene and drug delivery to the cardiovascular system. Adv Drug Deliv Rev 2008;60:1177-1192.
102. Fujii H, Li SH, Wu J, Miyagi Y, Yau TM, Rakowski H et al. Repeated and targeted transfer of angiogenic plasmids into the infarcted rat heart via ultrasound targeted microbubble destruction enhances cardiac repair. Eur Heart J 2011;32:2075-2084.
103. Suzuki J, Ogawa M, Takayama K, Taniyama Y, Morishita R, Hirata Y et al. Ultrasound-microbubble-mediated intercellular adhesion molecule-1 small interfering ribonucleic acid transfection attenuates neointimal formation after arterial injury in mice. J Am Coll Cardiol 2010;55:904-913.
104. Kupatt C. Nonviral intercellular adhesion molecule-1 small interfering ribonucleic acid sequences transfection in vivo how ultrasound bursts into therapy. J Am Coll Cardiol 2010;55:914-916.
105. Waxman S, Moreno R, Rowe KA, Verrier RL. Persistent primary coronary dilation induced by transatrial delivery of nitroglycerin into the pericardial space: a novel approach for local cardiac drug delivery. J Am Coll Cardiol 1999;33: 2073-2077.
106. Lazarous DF, Shou M, Stiber JA, Dadhania DM, Thirumurti V, Hodge E et al. Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovasc Res 1997;36:78-85. (Pubitemid 27463575)
107. Hamdi H, Furuta A, Bellamy V, Bel A, Puymirat E, Peyrard S et al. Cell delivery: intramyocardial injections or epicardial deposition? A head-to-head comparison. Ann Thorac Surg 2009;87:1196-1203.
108. Ladage D, Turnbull IC, Ishikawa K, Takewa Y, Rapti K, Morel C et al. Delivery of gelfoam-enabled cells and vectors into the pericardial space using a percutaneous approach in a porcine model. Gene Ther 2011;18:979-985.
109. Le Visage C, Gournay O, Benguirat N, Hamidi S, Chaussumier L, Mougeneot N et al. Mesenchymal stem cell delivery into rat infarcted myocardium using a porous polysaccharide-based scaffold: a quantitative comparison with endocardial injection. Tissue Eng Part A 2012;18:35-44.
110. Godier-Furnemont AF, Martens TP, Koeckert MS, Wan L, Parks J, Arai K et al. Composite scaffold provides a cell delivery platform for cardiovascular repair. Proc Natl Acad Sci USA 2011;108:7974-7979.